Sexuality and intimacy after gynecological cancer
Abstract Matters of sexuality and intimacy greatly impact quality of life of patients with gynecologic cancers. Vast amount of evidence exists showing that cancer dramatically impacts woman's sexuality, sexual functioning, intimate relationships and sense of self. Sexual functioning can be affe...
Gespeichert in:
Veröffentlicht in: | Maturitas 2010-05, Vol.66 (1), p.23-26 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 26 |
---|---|
container_issue | 1 |
container_start_page | 23 |
container_title | Maturitas |
container_volume | 66 |
creator | Ratner, Elena S Foran, Kelly A Schwartz, Peter E Minkin, Mary Jane |
description | Abstract Matters of sexuality and intimacy greatly impact quality of life of patients with gynecologic cancers. Vast amount of evidence exists showing that cancer dramatically impacts woman's sexuality, sexual functioning, intimate relationships and sense of self. Sexual functioning can be affected by illness, pain, anxiety, anger, stressful circumstances and medications. There is a growing acknowledgement that these needs are not being appropriately addressed by providers. With improvements in early detection, surgery and adjuvant therapy for gynecologic cancer, long term survival and cure are becoming possible. Quality of life is thus becoming a major issue for patients. Patients suffer from hot flashes, difficulty sleeping, loss of libido and intimacy, all resulting in significant morbidity and loss of quality of life. Using hormone replacement therapy in gynecologic cancer survivors is a topic a great debate. While limited studies are available to date, retrospective cohort reviews show no reported differences in overall or disease-free survival in patients using hormone replacements vs. controls in patients with ovarian cancer, endometrial cancer, cervical, vaginal or vulva cancer. Since safety of using HRT remains controversial and prospective studies are lacking, providers need to be able to provide alternatives to HRT. Centrally acting agents such as antiseizure agent gabapentin and selective serotonine re-uptake inhibitors, such as venlafaxine and fluoxitine have been demonstrated to show effectiveness in treating vasomotor symptoms and are easily tolerated. To address cardiovascular and osteoporosis risks of post-menopausal status, exercise, healthy diet, bisphosphonates, raloxifen and statins have been found to be effective. Psychotherapy plays an essential part in management of these issues. Review of the literature reveals recent trends among health psychologists to utilize psychoeducational interventions that include combined elements of cognitive and behavioral therapy with education and mindfulness training. Intervention studies have found positive effects from this approach, particularly within the areas of arousal, orgasm, satisfaction, overall well-being, and decreased depression. Many of patients’ issues are easy to address with either hormonal, non-hormonal or psychotherapy modifications. The essential part of success is the providers appreciation of this serous problem and willingness and comfort in addressing it. |
doi_str_mv | 10.1016/j.maturitas.2010.01.015 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733895419</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0378512210000423</els_id><sourcerecordid>733895419</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-a16b545afa3f742b0e87188180b2c7d99db6300f5c2104e3bcb3999e058e2e453</originalsourceid><addsrcrecordid>eNqNkUtLxDAQgIMo7vr4C7oX8dR1Jo9texFk8QWCB_Uc0nS6ZO22mrTi_ntTdlXwJAyEDF9mJt8wdoowRcDZxXK6Ml3vXWfClEPMAsZQO2yMWSoSiYi7bAwizRKFnI_YQQhLAFAg5D4bcRAgOOdjhk_02ZvadeuJacqJazq3MjZeqo78ZLFuyLZ1u3DW1BNrGkv-iO1Vpg50vD0P2cvN9fP8Lnl4vL2fXz0kVirVJQZnhZLKVEZUqeQFUJZilmEGBbdpmedlMRMAlbIcQZIobCHyPCdQGXGSShyy803dN9--9xQ6vXLBUl2bhto-6FSILFcS80imG9L6NgRPlX7z8Rd-rRH0oEsv9Y8uPejSgDGGHifbHn2xovLn3befCJxtAROigspHBS78cjydiThD5K42HEUjH468DtZR1FU6T7bTZev-Mczlnxq2ds1g_pXWFJZt75soXKMOXIN-GrY7LBfjXkFyIb4AwkegeQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733895419</pqid></control><display><type>article</type><title>Sexuality and intimacy after gynecological cancer</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><creator>Ratner, Elena S ; Foran, Kelly A ; Schwartz, Peter E ; Minkin, Mary Jane</creator><creatorcontrib>Ratner, Elena S ; Foran, Kelly A ; Schwartz, Peter E ; Minkin, Mary Jane</creatorcontrib><description>Abstract Matters of sexuality and intimacy greatly impact quality of life of patients with gynecologic cancers. Vast amount of evidence exists showing that cancer dramatically impacts woman's sexuality, sexual functioning, intimate relationships and sense of self. Sexual functioning can be affected by illness, pain, anxiety, anger, stressful circumstances and medications. There is a growing acknowledgement that these needs are not being appropriately addressed by providers. With improvements in early detection, surgery and adjuvant therapy for gynecologic cancer, long term survival and cure are becoming possible. Quality of life is thus becoming a major issue for patients. Patients suffer from hot flashes, difficulty sleeping, loss of libido and intimacy, all resulting in significant morbidity and loss of quality of life. Using hormone replacement therapy in gynecologic cancer survivors is a topic a great debate. While limited studies are available to date, retrospective cohort reviews show no reported differences in overall or disease-free survival in patients using hormone replacements vs. controls in patients with ovarian cancer, endometrial cancer, cervical, vaginal or vulva cancer. Since safety of using HRT remains controversial and prospective studies are lacking, providers need to be able to provide alternatives to HRT. Centrally acting agents such as antiseizure agent gabapentin and selective serotonine re-uptake inhibitors, such as venlafaxine and fluoxitine have been demonstrated to show effectiveness in treating vasomotor symptoms and are easily tolerated. To address cardiovascular and osteoporosis risks of post-menopausal status, exercise, healthy diet, bisphosphonates, raloxifen and statins have been found to be effective. Psychotherapy plays an essential part in management of these issues. Review of the literature reveals recent trends among health psychologists to utilize psychoeducational interventions that include combined elements of cognitive and behavioral therapy with education and mindfulness training. Intervention studies have found positive effects from this approach, particularly within the areas of arousal, orgasm, satisfaction, overall well-being, and decreased depression. Many of patients’ issues are easy to address with either hormonal, non-hormonal or psychotherapy modifications. The essential part of success is the providers appreciation of this serous problem and willingness and comfort in addressing it.</description><identifier>ISSN: 0378-5122</identifier><identifier>EISSN: 1873-4111</identifier><identifier>DOI: 10.1016/j.maturitas.2010.01.015</identifier><identifier>PMID: 20303222</identifier><identifier>CODEN: MATUDK</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Biological and medical sciences ; Endometrial cancer ; Female ; Female genital diseases ; Genital Neoplasms, Female - complications ; Genital Neoplasms, Female - therapy ; Gynecologic cancer ; Gynecology. Andrology. Obstetrics ; Hormone Replacement Therapy ; Humans ; Internal Medicine ; Intimacy ; Medical sciences ; Neoplasms - complications ; Neoplasms - therapy ; Obstetrics and Gynecology ; Ovarian cancer ; Psychologic modifications ; Psychotherapy ; Puberal and climacteric disorders (male and female) ; Sexual Dysfunction, Physiological - etiology ; Sexual Dysfunction, Physiological - therapy ; Sexual Dysfunctions, Psychological - etiology ; Sexual Dysfunctions, Psychological - therapy ; Sexual Partners - psychology ; Sexuality ; Sexuality - psychology ; Tumors</subject><ispartof>Maturitas, 2010-05, Vol.66 (1), p.23-26</ispartof><rights>2010</rights><rights>2015 INIST-CNRS</rights><rights>Published by Elsevier Ireland Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-a16b545afa3f742b0e87188180b2c7d99db6300f5c2104e3bcb3999e058e2e453</citedby><cites>FETCH-LOGICAL-c455t-a16b545afa3f742b0e87188180b2c7d99db6300f5c2104e3bcb3999e058e2e453</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.maturitas.2010.01.015$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22763541$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20303222$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ratner, Elena S</creatorcontrib><creatorcontrib>Foran, Kelly A</creatorcontrib><creatorcontrib>Schwartz, Peter E</creatorcontrib><creatorcontrib>Minkin, Mary Jane</creatorcontrib><title>Sexuality and intimacy after gynecological cancer</title><title>Maturitas</title><addtitle>Maturitas</addtitle><description>Abstract Matters of sexuality and intimacy greatly impact quality of life of patients with gynecologic cancers. Vast amount of evidence exists showing that cancer dramatically impacts woman's sexuality, sexual functioning, intimate relationships and sense of self. Sexual functioning can be affected by illness, pain, anxiety, anger, stressful circumstances and medications. There is a growing acknowledgement that these needs are not being appropriately addressed by providers. With improvements in early detection, surgery and adjuvant therapy for gynecologic cancer, long term survival and cure are becoming possible. Quality of life is thus becoming a major issue for patients. Patients suffer from hot flashes, difficulty sleeping, loss of libido and intimacy, all resulting in significant morbidity and loss of quality of life. Using hormone replacement therapy in gynecologic cancer survivors is a topic a great debate. While limited studies are available to date, retrospective cohort reviews show no reported differences in overall or disease-free survival in patients using hormone replacements vs. controls in patients with ovarian cancer, endometrial cancer, cervical, vaginal or vulva cancer. Since safety of using HRT remains controversial and prospective studies are lacking, providers need to be able to provide alternatives to HRT. Centrally acting agents such as antiseizure agent gabapentin and selective serotonine re-uptake inhibitors, such as venlafaxine and fluoxitine have been demonstrated to show effectiveness in treating vasomotor symptoms and are easily tolerated. To address cardiovascular and osteoporosis risks of post-menopausal status, exercise, healthy diet, bisphosphonates, raloxifen and statins have been found to be effective. Psychotherapy plays an essential part in management of these issues. Review of the literature reveals recent trends among health psychologists to utilize psychoeducational interventions that include combined elements of cognitive and behavioral therapy with education and mindfulness training. Intervention studies have found positive effects from this approach, particularly within the areas of arousal, orgasm, satisfaction, overall well-being, and decreased depression. Many of patients’ issues are easy to address with either hormonal, non-hormonal or psychotherapy modifications. The essential part of success is the providers appreciation of this serous problem and willingness and comfort in addressing it.</description><subject>Biological and medical sciences</subject><subject>Endometrial cancer</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Genital Neoplasms, Female - complications</subject><subject>Genital Neoplasms, Female - therapy</subject><subject>Gynecologic cancer</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Hormone Replacement Therapy</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Intimacy</subject><subject>Medical sciences</subject><subject>Neoplasms - complications</subject><subject>Neoplasms - therapy</subject><subject>Obstetrics and Gynecology</subject><subject>Ovarian cancer</subject><subject>Psychologic modifications</subject><subject>Psychotherapy</subject><subject>Puberal and climacteric disorders (male and female)</subject><subject>Sexual Dysfunction, Physiological - etiology</subject><subject>Sexual Dysfunction, Physiological - therapy</subject><subject>Sexual Dysfunctions, Psychological - etiology</subject><subject>Sexual Dysfunctions, Psychological - therapy</subject><subject>Sexual Partners - psychology</subject><subject>Sexuality</subject><subject>Sexuality - psychology</subject><subject>Tumors</subject><issn>0378-5122</issn><issn>1873-4111</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtLxDAQgIMo7vr4C7oX8dR1Jo9texFk8QWCB_Uc0nS6ZO22mrTi_ntTdlXwJAyEDF9mJt8wdoowRcDZxXK6Ml3vXWfClEPMAsZQO2yMWSoSiYi7bAwizRKFnI_YQQhLAFAg5D4bcRAgOOdjhk_02ZvadeuJacqJazq3MjZeqo78ZLFuyLZ1u3DW1BNrGkv-iO1Vpg50vD0P2cvN9fP8Lnl4vL2fXz0kVirVJQZnhZLKVEZUqeQFUJZilmEGBbdpmedlMRMAlbIcQZIobCHyPCdQGXGSShyy803dN9--9xQ6vXLBUl2bhto-6FSILFcS80imG9L6NgRPlX7z8Rd-rRH0oEsv9Y8uPejSgDGGHifbHn2xovLn3befCJxtAROigspHBS78cjydiThD5K42HEUjH468DtZR1FU6T7bTZev-Mczlnxq2ds1g_pXWFJZt75soXKMOXIN-GrY7LBfjXkFyIb4AwkegeQ</recordid><startdate>20100501</startdate><enddate>20100501</enddate><creator>Ratner, Elena S</creator><creator>Foran, Kelly A</creator><creator>Schwartz, Peter E</creator><creator>Minkin, Mary Jane</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100501</creationdate><title>Sexuality and intimacy after gynecological cancer</title><author>Ratner, Elena S ; Foran, Kelly A ; Schwartz, Peter E ; Minkin, Mary Jane</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-a16b545afa3f742b0e87188180b2c7d99db6300f5c2104e3bcb3999e058e2e453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Biological and medical sciences</topic><topic>Endometrial cancer</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Genital Neoplasms, Female - complications</topic><topic>Genital Neoplasms, Female - therapy</topic><topic>Gynecologic cancer</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Hormone Replacement Therapy</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Intimacy</topic><topic>Medical sciences</topic><topic>Neoplasms - complications</topic><topic>Neoplasms - therapy</topic><topic>Obstetrics and Gynecology</topic><topic>Ovarian cancer</topic><topic>Psychologic modifications</topic><topic>Psychotherapy</topic><topic>Puberal and climacteric disorders (male and female)</topic><topic>Sexual Dysfunction, Physiological - etiology</topic><topic>Sexual Dysfunction, Physiological - therapy</topic><topic>Sexual Dysfunctions, Psychological - etiology</topic><topic>Sexual Dysfunctions, Psychological - therapy</topic><topic>Sexual Partners - psychology</topic><topic>Sexuality</topic><topic>Sexuality - psychology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ratner, Elena S</creatorcontrib><creatorcontrib>Foran, Kelly A</creatorcontrib><creatorcontrib>Schwartz, Peter E</creatorcontrib><creatorcontrib>Minkin, Mary Jane</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Maturitas</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ratner, Elena S</au><au>Foran, Kelly A</au><au>Schwartz, Peter E</au><au>Minkin, Mary Jane</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sexuality and intimacy after gynecological cancer</atitle><jtitle>Maturitas</jtitle><addtitle>Maturitas</addtitle><date>2010-05-01</date><risdate>2010</risdate><volume>66</volume><issue>1</issue><spage>23</spage><epage>26</epage><pages>23-26</pages><issn>0378-5122</issn><eissn>1873-4111</eissn><coden>MATUDK</coden><abstract>Abstract Matters of sexuality and intimacy greatly impact quality of life of patients with gynecologic cancers. Vast amount of evidence exists showing that cancer dramatically impacts woman's sexuality, sexual functioning, intimate relationships and sense of self. Sexual functioning can be affected by illness, pain, anxiety, anger, stressful circumstances and medications. There is a growing acknowledgement that these needs are not being appropriately addressed by providers. With improvements in early detection, surgery and adjuvant therapy for gynecologic cancer, long term survival and cure are becoming possible. Quality of life is thus becoming a major issue for patients. Patients suffer from hot flashes, difficulty sleeping, loss of libido and intimacy, all resulting in significant morbidity and loss of quality of life. Using hormone replacement therapy in gynecologic cancer survivors is a topic a great debate. While limited studies are available to date, retrospective cohort reviews show no reported differences in overall or disease-free survival in patients using hormone replacements vs. controls in patients with ovarian cancer, endometrial cancer, cervical, vaginal or vulva cancer. Since safety of using HRT remains controversial and prospective studies are lacking, providers need to be able to provide alternatives to HRT. Centrally acting agents such as antiseizure agent gabapentin and selective serotonine re-uptake inhibitors, such as venlafaxine and fluoxitine have been demonstrated to show effectiveness in treating vasomotor symptoms and are easily tolerated. To address cardiovascular and osteoporosis risks of post-menopausal status, exercise, healthy diet, bisphosphonates, raloxifen and statins have been found to be effective. Psychotherapy plays an essential part in management of these issues. Review of the literature reveals recent trends among health psychologists to utilize psychoeducational interventions that include combined elements of cognitive and behavioral therapy with education and mindfulness training. Intervention studies have found positive effects from this approach, particularly within the areas of arousal, orgasm, satisfaction, overall well-being, and decreased depression. Many of patients’ issues are easy to address with either hormonal, non-hormonal or psychotherapy modifications. The essential part of success is the providers appreciation of this serous problem and willingness and comfort in addressing it.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>20303222</pmid><doi>10.1016/j.maturitas.2010.01.015</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0378-5122 |
ispartof | Maturitas, 2010-05, Vol.66 (1), p.23-26 |
issn | 0378-5122 1873-4111 |
language | eng |
recordid | cdi_proquest_miscellaneous_733895419 |
source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE |
subjects | Biological and medical sciences Endometrial cancer Female Female genital diseases Genital Neoplasms, Female - complications Genital Neoplasms, Female - therapy Gynecologic cancer Gynecology. Andrology. Obstetrics Hormone Replacement Therapy Humans Internal Medicine Intimacy Medical sciences Neoplasms - complications Neoplasms - therapy Obstetrics and Gynecology Ovarian cancer Psychologic modifications Psychotherapy Puberal and climacteric disorders (male and female) Sexual Dysfunction, Physiological - etiology Sexual Dysfunction, Physiological - therapy Sexual Dysfunctions, Psychological - etiology Sexual Dysfunctions, Psychological - therapy Sexual Partners - psychology Sexuality Sexuality - psychology Tumors |
title | Sexuality and intimacy after gynecological cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T12%3A44%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sexuality%20and%20intimacy%20after%20gynecological%20cancer&rft.jtitle=Maturitas&rft.au=Ratner,%20Elena%20S&rft.date=2010-05-01&rft.volume=66&rft.issue=1&rft.spage=23&rft.epage=26&rft.pages=23-26&rft.issn=0378-5122&rft.eissn=1873-4111&rft.coden=MATUDK&rft_id=info:doi/10.1016/j.maturitas.2010.01.015&rft_dat=%3Cproquest_cross%3E733895419%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733895419&rft_id=info:pmid/20303222&rft_els_id=1_s2_0_S0378512210000423&rfr_iscdi=true |